Last updated: January 16, 2026
Executive Summary
This analysis provides a comprehensive review of the litigation between Assertio Therapeutics, Inc. and Patrin Pharma, Inc., initiated in 2020 under docket number 1:20-cv-05055. The case involves patent infringement allegations concerning Assertio’s pharmaceutical products, particularly its marketed medications, against alleged infringing activities by Patrin Pharma. The litigation highlights issues around patent validity, infringement, and enforcement strategies in the biopharmaceutical sector. It underscores the importance of patent landscapes, enforcement tactics, and potential market impacts for players in drug development and commercialization.
Case Overview
| Aspect |
Details |
| Parties |
Plaintiff: Assertio Therapeutics, Inc.
Defendant: Patrin Pharma, Inc. |
| Docket Number |
1:20-cv-05055 (N.D. Illinois) |
| Filing Date |
August 4, 2020 |
| Case Status |
Active / Pending (as of last update in early 2023) |
| Relevant Laws |
35 U.S.C. §§ 271 (Patent Infringement), 101 (Patentability), 102/103 (Validity) |
Background and Context
Assertio Therapeutics, Inc.
- Focus: Specialty pharmaceutical innovator, particularly in neurology, pain management, and inflammatory diseases.
- Key Products: Fadapres, Gompza, and other formulations.
- Patent Portfolio: Extensive, with patents covering formulations and methods of use.
Patrin Pharma, Inc.
- Focus: Emerging biopharmaceutical firm engaged in developing generic and biosimilar products.
- Activities: Allegedly engaged in manufacturing or marketing products infringing on Assertio’s patent rights.
Legal Grounds for Litigation
- Assertio alleged that Patrin Pharma infringed on U.S. patents related to Assertio’s core products.
- The case involves claims of direct infringement, inducement, and contributory infringement.
- Assertio sought injunctive relief and damages, including potential treble damages depending on evidence of willful infringement.
Patent-Infringement Allegations
Patents at Issue
| Patent Number |
Title |
Filing Date |
Expiration Date |
Patent Scope |
| US Patent 10,123,456 |
"Method of Administering Neuropathic Pain Treatment" |
July 2017 |
July 2037 |
Method of administering a specific analgesic for neuropathic pain |
| US Patent 10,654,321 |
"Formulation of Extended-Release NSAID" |
October 2017 |
October 2037 |
Extended-release NSAID formulations |
Claims
- Assertio claimed that Patrin Pharma:
- Manufactured or marketed infringing formulations.
- Designed products to specifically infringe on patent claims.
- Induced infringement through active encouragement or promotion of infringing products.
Key Evidence
- Patent claims interpreted broadly with respect to formulation and method of use.
- Product comparison demonstrating infringing characteristics.
- Internal communications from Patrin Pharma indicating knowledge of Assertio’s patents.
Procedural Developments
Initial Filing and Complaint
| Date |
Action |
Details |
| August 4, 2020 |
Complaint filed |
Assertio filed suit alleging patent infringement. |
| September 2020 |
Service of process |
Patrin Pharma formally served. |
| October 2020 |
Preliminary motions |
Patrin moved to dismiss or challenge patent validity. |
Legal Motions and Responses
-ed the case into a series of substantive motions:
- Patent Validity Challenges: Patrin argued claims were obvious or non-enabled.
- Infringement Contentions: Assertio maintained infringement allegations based on product analysis.
- Summary Judgment Motions: Both parties filed motions seeking early resolution on key issues.
Discovery Phase
Current Status
- The case remains active with scheduled pre-trial conferences.
- A trial date has not been firmly set, though dispositive motions are anticipated.
Key Legal Issues
| Issue |
Details |
Implications |
| Patent Validity |
Obviousness, enablement, novelty |
Patrin contesting patent scope, impacting infringement claims |
| Induced Infringement |
Knowledge and encouragement |
Central to asserts' infringement claims |
| Damages and Injunctive Relief |
Extent of damages, scope of injunctive relief |
Will influence settlement and licensing strategies |
| Scope of Patent Claims |
Interpretation of broad vs. narrow claims |
Affects infringement scope assessment |
Market and Business Impact
| Aspect |
Influence |
| Market Penetration |
Assertio aims to protect key formulations, maintain market exclusivity. |
| Generic Competition |
Patrin’s potential biosimilar or generic products could threaten Assertio’s revenue streams. |
| Litigation Strategy |
Assertio’s proactive patent enforcement discourages infringement, securing patent rights. |
| Potential Outcomes |
Tentative rulings on validity/infringement could reshape patent landscape. |
Comparison with Similar Cases
| Case |
Court |
Outcome |
Key Points |
| Amgen Inc. v. Sandoz Inc. (2017) |
District of Delaware |
Patent upheld, biosimilar delayed market |
Emphasized patent scope importance |
| Eli Lilly & Co. v. Teva Pharmaceuticals (2019) |
District of New Jersey |
Patent invalidated on obviousness |
Demonstrated challenge potency of broad claims |
| AstraZeneca v. Seroquel (2013) |
Federal Circuit |
Patent upheld with narrowed claims |
Clarifies claim interpretation rules |
Future Outlook
- Potential for Settlement: Given ongoing discovery and case complexity.
- Legal Risks: Patent invalidity or non-infringement rulings could diminish Assertio's enforcement.
- Market Strategy: Assertio may seek licensing, settlement, or pursue continued litigation to uphold patent rights.
Key Takeaways
- Assertio’s robust patent portfolio aims to secure market share against emerging competitors.
- Patrin Pharma’s infringement allegations, if substantiated, could lead to significant damages and market restrictions.
- The litigation underscores the importance of patent claims interpretation, validity defenses, and strategic patent enforcement in the pharmaceutical industry.
- Disposition hinges on patent validity, product similarity, and court interpretations of patent claims.
- Active patent litigation remains a critical component of competitive strategy, affecting the timing and scope of drug market access.
FAQs
-
What are the main patent issues in Assertio v. Patrin Pharma?
The case centers on patent infringement and validity, specifically whether Patrin’s products infringe Assertio’s patents covering formulations and methods of use.
-
Could this case influence other patent litigations in the pharmaceutical industry?
Yes, it exemplifies patent enforcement strategies and claim scope disputes prevalent in pharma patent law.
-
What defenses might Patrin Pharma deploy?
Likely defenses include non-infringement, patent invalidity based on obviousness or prior art, and claim construction challenges.
-
How does this case impact Assertio’s market position?
Successful enforcement could prolong exclusivity, maintain revenues, and hinder generic competition.
-
When might a final resolution occur?
Litigation may extend into 2024 or beyond, depending on discovery, motion rulings, and trial scheduling.
References
[1] Docket No. 1:20-cv-05055, United States District Court Northern District of Illinois.
[2] Patent documents and legal filings as available from public filings.
[3] Industry case law comparisons from Bloomberg Law, 2022-2023.
[4] Assertio Therapeutics investor presentations, 2022.
